Daewoong Pharmaceutical vs Hanmi Pharmaceutical
Daewoong Pharmaceutical holds the stronger position right now because its pressure comes from taking share off AbbVie, Takeda and Sanofi, while Hanmi Pharmaceutical's biggest risk is an internal fight between its founding family and management, not the market itself.
Daewoong Pharmaceutical
Korean pharma maker of Nabota botulinum toxin, Fexuclue GERD drug, and Envlo diabetes pill
Hanmi Pharmaceutical
Korean pharma maker of long-acting peptide drugs, generics, and an obesity drug in development
Dimension by dimension
| Dimension | Daewoong Pharmaceutical | Hanmi Pharmaceutical |
|---|---|---|
| Staying power of the core product | Nabota, Fexuclue and Envlo also show durable competitive protection and are seen as unlikely to be absorbed by AI. | Diabetes, oncology and obesity drugs with global licensing deals give Hanmi durable competitive protection, with no sign AI can absorb the product line. |
| Exposure to AI | Daewoong's drug pipeline carries the same unlikely rating. | Hanmi's drug pipeline is rated unlikely to be absorbed by AI. |
| How easily a giant copies them | Daewoong's position is also rated blocked against copying. | Hanmi's position is rated blocked against copying by a larger player. |
| Pressure from rivals | Daewoong faces heavier direct market pressure than Hanmi does, competing directly against AbbVie, Takeda and Sanofi, but it is gaining share from those rivals rather than losing it. | Hanmi's main source of risk is internal, a founding family dispute involving Shin Dong-kuk, rather than competitive share loss to rivals. |
| Financial footing | Daewoong posted FY2025 revenue of 1.57tn KRW, up 10.42%, with net income up a striking 691.8% year over year. | Hanmi posted FY2025 revenue of USD 1.15B with operating profit up 19.2% and net profit up 33.9% year over year. |
| Internal stability | No internal governance conflict is noted for Daewoong in the evidence. | Hanmi is dealing with a governance conflict between the founding family and Shin Dong-kuk, which is a source of internal uncertainty. |
Questions people ask
- Hanmi Pharmaceutical vs Daewoong Pharmaceutical, which is safer for the AI era?
- Both companies score well on AI exposure, since drug development is unlikely to be absorbed by AI and both are rated blocked against being copied by a larger player. The difference is that Hanmi's main risk is an internal family governance fight, while Daewoong's pressure comes from external competition it is currently winning against AbbVie, Takeda and Sanofi.
- Does AI threaten Hanmi Pharmaceutical or Daewoong Pharmaceutical?
- Neither company is seen as vulnerable to AI absorbing its products. Both Hanmi's diabetes, oncology and obesity drugs and Daewoong's Nabota, Fexuclue and Envlo are rated unlikely to be replaced by AI.
- Who is growing faster, Hanmi or Daewoong?
- Hanmi grew FY2025 revenue to USD 1.15B with operating profit up 19.2% and net profit up 33.9%. Daewoong grew FY2025 revenue by 10.42% to 1.57tn KRW, with net income jumping 691.8%, a much larger swing in profit growth.
- What is the biggest risk for Hanmi Pharmaceutical?
- The biggest risk noted for Hanmi is not competition from rivals but an internal governance conflict between the founding family and Shin Dong-kuk. There is no direct evidence of Hanmi losing customers to competitors.
Other comparisons with these companies